Home Cart Sign in  
Chemical Structure| 13463-28-0 Chemical Structure| 13463-28-0

Structure of Eriocitrin
CAS No.: 13463-28-0

Chemical Structure| 13463-28-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Eriocitrin is a natural product isolated and purified from the fruits of Citrus sinensis (L.) Osbeck with antioxidative activity.

Synonyms: Eriodictioside; eriodictyol 7-rutinoside; Eriocitrin, Eriodictioside, Eriodictyol 7-O-rutinoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Eriocitrin

CAS No. :13463-28-0
Formula : C27H32O15
M.W : 596.53
SMILES Code : O=C1C[C@@H](C2=CC=C(O)C(O)=C2)OC3=C1C(O)=CC(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O5)O4)=C3
Synonyms :
Eriodictioside; eriodictyol 7-rutinoside; Eriocitrin, Eriodictioside, Eriodictyol 7-O-rutinoside
MDL No. :MFCD00017472

Safety of Eriocitrin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human umbilical vein endothelial cells (HUVECs) 25-100 µM 24 hours Evaluate the effect of Eriocitrin on apoptosis in HUVECs, showing evident induction of cell apoptosis. Nutrients. 2024 Apr 8;16(7):1091
Human umbilical vein endothelial cells (HUVECs) 25-100 µM 24 hours Assess the effect of Eriocitrin on HUVECs migration, showing significant reduction in migrating cell numbers. Nutrients. 2024 Apr 8;16(7):1091
Human umbilical vein endothelial cells (HUVECs) 25-100 µM 24 hours Evaluate the effect of Eriocitrin on tube formation in HUVECs, showing significant inhibition of tubular structure formation. Nutrients. 2024 Apr 8;16(7):1091
Human umbilical vein endothelial cells (HUVECs) 25-100 µM 48 hours Assess the cytotoxicity of Eriocitrin on HUVECs, showing no significant LDH release at tested concentrations. Nutrients. 2024 Apr 8;16(7):1091
Human umbilical vein endothelial cells (HUVECs) 25-100 µM 24 hours Evaluate the effect of Eriocitrin on HUVECs proliferation, showing no significant effect on cell viability at tested concentrations. Nutrients. 2024 Apr 8;16(7):1091
H1299 cells 50 μM 24 hours To evaluate the effect of Eriocitrin on the EMT process of H1299 cells, the results showed that Eriocitrin upregulated E-cadherin expression and downregulated N-cadherin and vimentin expression. Aging (Albany NY). 2023 Oct 2;15(19):10089-10104
A549 cells 50 μM 24 hours To evaluate the effect of Eriocitrin on the EMT process of A549 cells, the results showed that Eriocitrin upregulated E-cadherin expression and downregulated N-cadherin and vimentin expression. Aging (Albany NY). 2023 Oct 2;15(19):10089-10104
H1299 cells 0, 25, 50, 75, 100 μM 24 or 48 hours To evaluate the effect of Eriocitrin on the migration ability of H1299 cells, the results showed that Eriocitrin significantly inhibited cell migration. Aging (Albany NY). 2023 Oct 2;15(19):10089-10104
A549 cells 0, 25, 50, 75, 100 μM 24 or 48 hours To evaluate the effect of Eriocitrin on the migration ability of A549 cells, the results showed that Eriocitrin significantly inhibited cell migration. Aging (Albany NY). 2023 Oct 2;15(19):10089-10104
H1299 cells 0, 5, 10, 20, 40, 80, 160 μM 24 or 48 hours To evaluate the effect of Eriocitrin on the viability of H1299 cells, the results showed that Eriocitrin significantly inhibited cell viability in a concentration-dependent manner. Aging (Albany NY). 2023 Oct 2;15(19):10089-10104
A549 cells 0, 5, 10, 20, 40, 80, 160 μM 24 or 48 hours To evaluate the effect of Eriocitrin on the viability of A549 cells, the results showed that Eriocitrin significantly inhibited cell viability in a concentration-dependent manner. Aging (Albany NY). 2023 Oct 2;15(19):10089-10104
Erythrocytes 10–100 μM 24 hours To evaluate the hemolytic and eryptotic effects of ERN on erythrocytes, results showed significant hemolysis and eryptosis Pharmaceuticals (Basel). 2023 Dec 2;16(12):1681
Caco-2 cells 10 µM 24 hours To evaluate the anti-inflammatory effects of FM and DFM on IL-1β-induced inflammatory response. Results showed that FM and DFM significantly reduced the release of IL-6, IL-8, and NO, comparable to or stronger than the anti-inflammatory drug dexamethasone. Antioxidants (Basel). 2021 Jan 20;10(2):140

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Chick embryos Chick embryo chorioallantoic membrane (CAM) model Topical administration 5-50 nmol/egg Single dose, observed for 2 days Evaluate the effect of Eriocitrin on angiogenesis in chick embryos, showing significant suppression of new blood vessel formation. Nutrients. 2024 Apr 8;16(7):1091

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02627547 Healthy Not Applicable Completed - United Kingdom ... More >> University of Glasgow School of Medicine Glasgow, United Kingdom Less <<
NCT03482401 Breast Cancer Not Applicable Active, not recruiting June 1, 2019 Spain ... More >> Hospital General Universitario Reina Sofía Murcia, Spain, 30003 Less <<
NCT03215043 Pre Diabetes Not Applicable Recruiting June 28, 2019 Brazil ... More >> Sao Paulo State University "Julio de Mesquita Filho", Faculdade de Ciências Farmacêuticas Recruiting Araraquara, Sao Paulo, Brazil, 14800-903 Contact: Thais B Cesar, Ph.D.    +55 16 3301-6927    tcesar@fcfar.unesp.br Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.68mL

0.34mL

0.17mL

8.38mL

1.68mL

0.84mL

16.76mL

3.35mL

1.68mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories